An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 in Healthy Adult Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Area under the plasma concentration-time curve during dosing interval (AUCt)
研究概览
简要总结
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228A in healthy subjects.
详细描述
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-228A compared with coadministration AD-2281 and AD-2282 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- •The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
排除标准
- •Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- •Other exclusions applied
研究组 & 干预措施
Sequence B
Period 1 : Test Drug(AD-228A), Period 2 : Reference Drug(AD-2281 and AD-2282)
干预措施: AD-228A (Drug)
Sequence A
Period 1 : Reference Drug(AD-2281 and AD-2282), Period 2 : Test Drug(AD-228A)
干预措施: AD-228A (Drug)
Sequence A
Period 1 : Reference Drug(AD-2281 and AD-2282), Period 2 : Test Drug(AD-228A)
干预措施: AD-2281 and AD-2282 (Drug)
Sequence B
Period 1 : Test Drug(AD-228A), Period 2 : Reference Drug(AD-2281 and AD-2282)
干预措施: AD-2281 and AD-2282 (Drug)
结局指标
主要结局
Area under the plasma concentration-time curve during dosing interval (AUCt)
时间窗: pre-dose to 72 hours
AUCt of AD-228A
Maximum concentration of drug in plasma (Cmax)
时间窗: pre-dose to 72 hours
Cmax of AD-228A
次要结局
未报告次要终点